Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo-Free stem cell transplant could change thalassemia treatment

NCT ID NCT06743477

Disease control Sponsor: Hu Peng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early study tests a new type of stem cell transplant called 'super transplant' for children aged 7-12 with severe thalassemia. Unlike standard transplants, this one does not require chemotherapy beforehand and aims to avoid graft-versus-host disease. Only 5 participants will be enrolled to see if donor cells can safely take hold.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Supergraft (donor stem cells given without pre-transplant chemotherapy)
What this could lead to
If it works, this could point toward a safer, simpler stem cell transplant for thalassemia patients who cannot have standard transplants.
What could go wrong
This is a very early, tiny trial (only 5 people). The approach is new and unproven in humans, so it may not work or could have unknown risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient inclusion criteria : * Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types; * Age between 7-12 years old, male or female not limited; Weight\<40kg * The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell transplantation treatment; And patients who unconditionally or refuse to undergo gene therapy for thalassemia; * There are HLA matched or mismatched donors who meet the donor criteria through physical examination; * The patient and their family agree to receive super transplantation treatment and sign a written informed consent form before the transplantation trial. （2） Exclusion criteria for patients: * Psychiatric patients; * Participants in clinical trials of other drugs within the past month; * There are no suitable HLA mismatched donors available. * Other researchers have determined that they are not suitable to participate in this study. （3） Supplier screening criteria: * HLA typing matches the patient's haplotype * KIR configuration * NIMA * DSA negative * Routine physical examination * Genetic screening for carriers of thalassemia, mild or no carriers of thalassemia * Sign the informed consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe mediterranean anemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta-thalassemia major thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stem cell transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yunnan First People's Hospital

    RECRUITING

    Kunming, Yunnan, 650000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.